Atypical carcinoid of the larynx and expressions of proteins associated with molecular targeted therapy

• Published in: Auris, nasus, larynx nasus, larynx, 2011-02, Vol.38 (1), p.123-126
• Main Authors: Kanazawa, Takeharu, Nokubi, Mitsuhiro, Takeoda, Katsuji, Kodama, Kozue, Usubuchi, Hajime, Iino, Yukiko
• Format: Article
• Language: English
• Subjects: Aged; Atypical laryngeal carcinoid; Biomarkers - analysis; Carcinoid Tumor - chemistry; Carcinoid Tumor - drug therapy; Case report; Humans; Immunohistochemical analysis; Immunohistochemistry; Laryngeal Neoplasms - chemistry; Laryngeal Neoplasms - drug therapy; Male; Molecular Targeted Therapy; Otolaryngology; Receptor, Epidermal Growth Factor - analysis; Receptors, Platelet-Derived Growth Factor - analysis; Vascular Endothelial Growth Factor Receptor-2 - analysis
• ISSN: 0385-8146; 1879-1476
• DOI: 10.1016/j.anl.2010.05.008

Abstract Objective We reported an extremely rare case of atypical laryngeal carcinoid, and examined the expression of several proteins for application of molecular targeted therapy. Method Case report and review of the literature concerning atypical carcinoid arising from the larynx. The expressions of proteins were determined by immunohistochemical analysis. Results We present here a case of atypical laryngeal carcinoid in a 79-year-old Japanese man, which was completely resected, and with no evidence of recurrence. On immunohistochemical analysis, neoplastic elements revealed, strong positivity for platelet-derived growth factor receptor α (PDGFRα), vascular endothelial growth factor receptor 2 (VEGFR2), and epidermal growth factor receptor (EGFR), and were mild positivity for KIT. Conclusion Our findings suggest that atypical laryngeal carcinoid could be completely removed if it is located in the limited lesion. PDGFRα, VEGFR2, and EGFR expressions in this case provide the evidence that atypical laryngeal carcinoid is the candidate for molecular targeted therapy, although further investigations are necessary.